Operaciones internas en acciones estadounidenses | Royalty Pharma divulgó el 4 de marzo cuatro transacciones internas de la compañía

2026年3月4日， Royalty Pharma（RPRX）disclosed 4 transactions involving company insiders. The executive Coyne Terrance P. sold 22,500 shares on March 2, 2026.

【Recent Insider Transactions】

【Company Information】

Royalty Pharma plc was incorporated on February 6, 2020, under the laws of England and Wales. The company is the largest buyer of biopharmaceutical royalties and a major funder of innovation in the biopharmaceutical sector. Since its founding in 1996, the company has been a pioneer in the royalty market, collaborating with innovators from academic institutions, research hospitals, and nonprofit organizations (from small biotechnology firms to global leading pharmaceutical companies). The company has gathered a portfolio of royalties that entitle them to payments based directly on the top-line sales of many industry-leading therapies, including Imbruvica, Januvia, Kalydeco, Trikafta, Truvada, Tysabri, and Xtandi. The company funds innovation in the biopharmaceutical industry directly or indirectly, both when they collaborate with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and when they acquire existing royalties from original innovators.